Meta-Analysis Comparing the Effect of Drug-Eluting Versus Bare Metal Stents on Risk of Acute Myocardial Infarction During Follow-Up

American Journal of Cardiology

Volumn 99, Issue 5, 2007, Pages 621-625

  Moreno, Raúl ^a   Fernández, Cristina ^b   Calvo, Luis ^a   Sánchez Recalde, Angel ^a   Galeote, Guillermo ^a   Sanchez Aquino, Rosa ^a   Alfonso, Fernando ^b   Macaya, Carlos ^b   López Sendón, José L ^a  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b HOSPITAL CLÍNICO SAN CARLOS   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLIMUS; EVEROLIMUS; PACLITAXEL; RAPAMYCIN; RAPAMYCIN DERIVATIVE; TIROFIBAN; UNCLASSIFIED DRUG; ZOTAROLIMUS;

ACUTE HEART INFARCTION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL TRIAL; COMPARATIVE STUDY; CORONARY STENT; DRUG EFFECT; DRUG ELUTING STENT; FOLLOW UP; HUMAN; IMPLANTATION; INCIDENCE; META ANALYSIS; PRIORITY JOURNAL; RESTENOSIS; REVASCULARIZATION; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

EQUIPMENT DESIGN; FOLLOW-UP STUDIES; HUMANS; IMMUNOSUPPRESSIVE AGENTS; MYOCARDIAL INFARCTION; RANDOMIZED CONTROLLED TRIALS; RISK ASSESSMENT; STENTS;

EID: 33847045167     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2006.09.110     Document Type: Article

References (9)

1. Bossi I., Klersy C., Black A., Cortina R., Choussat R., Cassagneau B., Jordan C., Laborde J.C., Laurent J.P., Bernies M., Fajadet J., and Marco J. In-stent restenosis: long term outcome and predictors of subsequent target lesion revascularization after repeat balloon angiplasty. J Am Coll Cardiol 35 (2000) 1569-1576
2. Walters D.L., Harding S.A., Walsh C.R., Wong P., Pomerantsev E., and Jang I.K. Acute coronary syndrome is a common clinical presentation of in-stent restenosis. Am J Cardiol 89 (2002) 491-494
3. Alfonso F., Auge J.M., Zueco J., Bethencourt A., Lopez-Minguez J.R., Hernandez J.M., Bullones J.A., Calvo I., Esplugas E., Perez-Vizcayno M.J., et al., RIBS investigators. Long-term results (three to five years) of the Restenosis Intra-stent: Balloon angioplasty versus elective Stenting (RIBS) randomized study. J Am Coll Cardiol 46 (2005) 756-760
4. Popma J.J., Suntharalingam M., Lansky A.J., Heuser R.R., Speiser B., Teirstein P.S., Massullo V., Bass T., Henderson R., Silber S., et al., Stents And Radiation Therepy (START) Investigators. Randomized trial of 90Sr/90Y beta-radiation versus placebo control for treatment of in-stent restenosis. Circulation 106 (2002) 1090-1096
5. Ajani A.E., Waksman R., Sharma A.K., Heuser R.R., Speiser B., Teirstein P.S., Massullo V., Bass T., Henderson R., Silber S., et al., Stents And Radiation Therepy (START) Investigators. Usefulness of periprocedural creatinine phosphokinase-MB release to predict adverse outcomes after intracoronary radiation therapy for in-stent restenosis. Am J Cardiol 93 (2004) 313-317
6. Pache J., Dibra A., Mehilli J., Dirschinger J., Schömig A., and Kastrati A. Drug-eluting stents compared with thin-strut bare stents for the reduction of restenosis: a prospective, randomized trial. Eur Heart J 26 (2005) 1262-1268
7. Moreno R. Drug-eluting stents and other anti-restenosis devices. Rev Esp Cardiol 58 (2005) 842-862
8. Babapulle M.N., Joseph L., Belisle P., Brophy J.M., and Eisenberg M.J. A hierarchical Bayesian meta-analysis of randomised clinical trials of drug-eluting stents. Lancet 364 (2004) 583-591
9. Moreno P.R., Palacios I.F., Leon M.B., Rhodes H., Fuster V., and Fallon J.T. Histopathologic comparison of human coronary in-stent and post-balloon angioplasty restenotic tissue. Am J Cardiol 84 (1999) 462-466